search icon
pasg-img

Passage Bio Inc, Common Stock

PASG

NAQ

$0.423

-$0.03

(-6.64%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$21.68M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
179.19K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.68
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.26 L
$1.33 H
$0.423

About Passage Bio Inc, Common Stock

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePASGSectorS&P500
1-Week Return29.5%1.39%1.18%
1-Month Return44.91%-4.97%6.44%
3-Month Return-12.8%-11.13%-0.73%
6-Month Return-60.03%-10.21%-2.01%
1-Year Return-62.04%-6.5%12.12%
3-Year Return-74.91%0.1%42.84%
5-Year Return-97.95%28.49%93.86%
10-Year Return-97.97%76.62%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue800.00K1.54M3.68M3.72M3.08M[{"date":"2020-12-31","value":21.5,"profit":true},{"date":"2021-12-31","value":41.47,"profit":true},{"date":"2022-12-31","value":98.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":82.8,"profit":true}]
Gross Profit(800.00K)(1.54M)(3.68M)(3.72M)-[{"date":"2020-12-31","value":-80000000,"profit":false},{"date":"2021-12-31","value":-154300000,"profit":false},{"date":"2022-12-31","value":-367900000,"profit":false},{"date":"2023-12-31","value":-372100000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses111.90M177.73M135.39M108.39M65.17M[{"date":"2020-12-31","value":62.96,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.18,"profit":true},{"date":"2023-12-31","value":60.99,"profit":true},{"date":"2024-12-31","value":36.67,"profit":true}]
Operating Income(112.90M)(185.73M)(138.39M)(108.39M)(70.40M)[{"date":"2020-12-31","value":-11290200000,"profit":false},{"date":"2021-12-31","value":-18572900000,"profit":false},{"date":"2022-12-31","value":-13839400000,"profit":false},{"date":"2023-12-31","value":-10838900000,"profit":false},{"date":"2024-12-31","value":-7040000000,"profit":false}]
Total Non-Operating Income/Expense1.34M686.00K4.54M--[{"date":"2020-12-31","value":29.53,"profit":true},{"date":"2021-12-31","value":15.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(112.23M)(185.39M)(136.13M)(102.06M)(64.77M)[{"date":"2020-12-31","value":-11223200000,"profit":false},{"date":"2021-12-31","value":-18538600000,"profit":false},{"date":"2022-12-31","value":-13612500000,"profit":false},{"date":"2023-12-31","value":-10206200000,"profit":false},{"date":"2024-12-31","value":-6476700000,"profit":false}]
Income Taxes(470.00K)6.11M731.00K5.39M(1.00)[{"date":"2020-12-31","value":-7.69,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":11.96,"profit":true},{"date":"2023-12-31","value":88.16,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(111.76M)(191.50M)(136.86M)--[{"date":"2020-12-31","value":-11176200000,"profit":false},{"date":"2021-12-31","value":-19150000000,"profit":false},{"date":"2022-12-31","value":-13685600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(112.23M)(185.79M)(136.68M)(112.38M)(64.77M)[{"date":"2020-12-31","value":-11223200000,"profit":false},{"date":"2021-12-31","value":-18578700000,"profit":false},{"date":"2022-12-31","value":-13667800000,"profit":false},{"date":"2023-12-31","value":-11237500000,"profit":false},{"date":"2024-12-31","value":-6476700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(111.76M)(191.50M)(136.86M)(102.06M)(64.77M)[{"date":"2020-12-31","value":-11176200000,"profit":false},{"date":"2021-12-31","value":-19150000000,"profit":false},{"date":"2022-12-31","value":-13685600000,"profit":false},{"date":"2023-12-31","value":-10206200000,"profit":false},{"date":"2024-12-31","value":-6476700000,"profit":false}]
EPS (Diluted)(3.08)(3.48)(2.50)(1.86)(1.00)[{"date":"2020-12-31","value":-308,"profit":false},{"date":"2021-12-31","value":-348,"profit":false},{"date":"2022-12-31","value":-250,"profit":false},{"date":"2023-12-31","value":-186,"profit":false},{"date":"2024-12-31","value":-99.55,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PASG
Cash Ratio 3.55
Current Ratio 3.74

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PASG
ROA (LTM) -32.20%
ROE (LTM) -75.07%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PASG
Debt Ratio Lower is generally better. Negative is bad. 0.46
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.54

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PASG
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.60
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.87

FAQs

What is Passage Bio Inc share price today?

Passage Bio Inc (PASG) share price today is $0.423

Can Indians buy Passage Bio Inc shares?

Yes, Indians can buy shares of Passage Bio Inc (PASG) on Vested. To buy Passage Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PASG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Passage Bio Inc be purchased?

Yes, you can purchase fractional shares of Passage Bio Inc (PASG) via the Vested app. You can start investing in Passage Bio Inc (PASG) with a minimum investment of $1.

How to invest in Passage Bio Inc shares from India?

You can invest in shares of Passage Bio Inc (PASG) via Vested in three simple steps:

  • Click on Sign Up or Invest in PASG stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Passage Bio Inc shares
What is Passage Bio Inc 52-week high and low stock price?

The 52-week high price of Passage Bio Inc (PASG) is $1.33. The 52-week low price of Passage Bio Inc (PASG) is $0.26.

What is Passage Bio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Passage Bio Inc (PASG) is 0.60

What is the Market Cap of Passage Bio Inc?

The market capitalization of Passage Bio Inc (PASG) is $21.68M

What is Passage Bio Inc’s stock symbol?

The stock symbol (or ticker) of Passage Bio Inc is PASG

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top